Core Viewpoint - HeartTech Medical (02291) reported strong mid-term performance with a revenue of 330 million RMB, reflecting a year-on-year growth of 32.4%, and a net profit attributable to shareholders of 182 million RMB, up 29.8% [1] Financial Performance - Revenue reached 330 million RMB, representing a 32.4% increase year-on-year [1] - Net profit attributable to shareholders was 182 million RMB, showing a growth of 29.8% [1] - Basic earnings per share stood at 0.5249 RMB [1] Product Portfolio - The company has a total of 30 marketed products including occluders, heart valves, and accessories [1] - There are 4 products under registration review and preparation, with an additional 28 products in various stages of research and development [1] Market Position and Growth Potential - CITIC Securities highlighted HeartTech Medical's comprehensive layout in the structural heart disease sector, covering areas such as congenital heart disease occluders, stroke, valves, and heart failure [1] - The company has a rich pipeline in the valve sector, with TAVR products already approved for market [1] - HeartTech Medical is positioned in the biodegradable aortic occluder market, which is expected to have strong overseas licensing potential due to its leading technology and proprietary intellectual property [1]
港股异动 | 心泰医疗(02291)午后涨近10% 中期纯利同比增长29.8% 可降解封堵器技术存在BD潜力